BIOLASE, INC. (NASDAQ:BIOL) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

ME Staff 8-k
-
0
BIOLASE, INC. (NASDAQ:BIOL) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

BIOLASE, INC. (NASDAQ:BIOL) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On November 14, 2019, the Board of Directors (the “Board”) of Biolase, Inc. (the “Company”) elected Michael DiTolla to the Board.

Michael DiTolla, 55, is currently Vice President of Clinical Affairs for AEGIS Communications. From 2015 to 2017, Dr. DiTolla served as Director of Clinical Affairs for Dentsply Sirona, and from 2001 to 2016 he served as Director of Clinical Education and Research at Glidewell Laboratories. Prior to his dental executive experience, Dr. DiTolla practiced restorative and esthetic dentistry from 1988 to 2001.

Dr. DiTolla was awarded Fellowship in the Academy of General Dentistry in 1995. He received his Bachelor of Science in Biology from Occidental College and a Doctor of Dental Surgery from University of the Pacific School of Dentistry.

There are no understandings or arrangements between Dr. DiTolla or any other person and the Company or any of its subsidiaries to which Dr. DiTolla was selected to serve as a director of the Company. There are no family relationships between Dr. DiTolla and any director, executive officer or person nominated or chosen by the Company to become a director or executive officer, and there are no transactions between Dr. DiTolla or any of his immediate family members and the Company or any of its subsidiaries.

to the terms of the Company’s 2018 Long-Term Incentive Plan, upon his election to the Board, Dr. DiTolla received an automatic award of 98,738 stock-settled restricted stock units, which fully vest on May 15, 2020. Upon vesting, each unit shall be settled with one share of Company’s Common Stock.

Item 7.01 Regulation FD Disclosure.

On November 15, 2019, the Company issued a press release announcing the election of Dr. DiTolla to the Board, a copy of which is attached as Exhibit 99.1 to this Current Report on Form 8-K.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

2


BIOLASE, INC Exhibit
EX-99.1 2 d79302dex991.htm EX-99.1 EX-99.1 Exhibit 99.1   BIOLASE APPOINTS MICHAEL DITOLLA,…
To view the full exhibit click here

About BIOLASE, INC. (NASDAQ:BIOL)

BIOLASE, Inc. (BIOLASE) is a medical device company that develops, manufactures, markets and sells laser systems in dentistry and medicine. The Company markets, sells, and distributes dental imaging equipment, including cone beam digital x-rays and computer-aided design (CAD)/computer-aided manufacturing (CAM) intra-oral scanners, in-office, chair-side milling machines and three-dimensional (3-D) printers. It offers two categories of laser system products: WaterLase (all-tissue) systems and Diode (soft tissue) systems. Its brand, WaterLase, uses a combination of water and laser energy to perform procedures performed using drills, scalpels, and other traditional dental instruments for cutting soft and hard tissue. It also offers its Diode laser systems to perform soft tissue, pain therapy, and cosmetic procedures, including teeth whitening. Its Waterlase and Diode systems use disposable laser tips of differing sizes and shapes depending on the procedures being performed.